These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

267 related items for PubMed ID: 22864238

  • 1. Insights on cytochrome p450 enzymes and inhibitors obtained through QSAR studies.
    Sridhar J, Liu J, Foroozesh M, Stevens CL.
    Molecules; 2012 Aug 03; 17(8):9283-305. PubMed ID: 22864238
    [Abstract] [Full Text] [Related]

  • 2. Pharmacophore and three-dimensional quantitative structure activity relationship methods for modeling cytochrome p450 active sites.
    Ekins S, de Groot MJ, Jones JP.
    Drug Metab Dispos; 2001 Jul 03; 29(7):936-44. PubMed ID: 11408357
    [Abstract] [Full Text] [Related]

  • 3. Computational models for predicting interactions with cytochrome p450 enzyme.
    Arimoto R.
    Curr Top Med Chem; 2006 Jul 03; 6(15):1609-18. PubMed ID: 16918472
    [Abstract] [Full Text] [Related]

  • 4. A Mechanism of O-Demethylation of Aristolochic Acid I by Cytochromes P450 and Their Contributions to This Reaction in Human and Rat Livers: Experimental and Theoretical Approaches.
    Stiborová M, Bárta F, Levová K, Hodek P, Schmeiser HH, Arlt VM, Martínek V.
    Int J Mol Sci; 2015 Nov 18; 16(11):27561-75. PubMed ID: 26593908
    [Abstract] [Full Text] [Related]

  • 5. Structure-function relationships of inhibition of human cytochromes P450 1A1, 1A2, 1B1, 2C9, and 3A4 by 33 flavonoid derivatives.
    Shimada T, Tanaka K, Takenaka S, Murayama N, Martin MV, Foroozesh MK, Yamazaki H, Guengerich FP, Komori M.
    Chem Res Toxicol; 2010 Dec 20; 23(12):1921-35. PubMed ID: 21053930
    [Abstract] [Full Text] [Related]

  • 6. In silico studies of polyaromatic hydrocarbon inhibitors of cytochrome P450 enzymes 1A1, 1A2, 2A6, and 2B1.
    Sridhar J, Jin P, Liu J, Foroozesh M, Stevens CL.
    Chem Res Toxicol; 2010 Mar 15; 23(3):600-7. PubMed ID: 20078084
    [Abstract] [Full Text] [Related]

  • 7. Spectral modification and catalytic inhibition of human cytochromes P450 1A1, 1A2, 1B1, 2A6, and 2A13 by four chemopreventive organoselenium compounds.
    Shimada T, Murayama N, Tanaka K, Takenaka S, Guengerich FP, Yamazaki H, Komori M.
    Chem Res Toxicol; 2011 Aug 15; 24(8):1327-37. PubMed ID: 21732699
    [Abstract] [Full Text] [Related]

  • 8. Binding and Metabolism of Brominated Flame Retardant β-1,2-Dibromo-4-(1,2-dibromoethyl)cyclohexane in Human Microsomal P450 Enzymes: Insights from Computational Studies.
    Ma G, Yu H, Han C, Jia Y, Wei X, Wang Z.
    Chem Res Toxicol; 2020 Jun 15; 33(6):1487-1496. PubMed ID: 32243142
    [Abstract] [Full Text] [Related]

  • 9. In vitro metabolism and drug interaction potential of a new highly potent anti-cytomegalovirus molecule, CMV423 (2-chloro 3-pyridine 3-yl 5,6,7,8-tetrahydroindolizine I-carboxamide).
    Bournique B, Lambert N, Boukaiba R, Martinet M.
    Br J Clin Pharmacol; 2001 Jul 15; 52(1):53-63. PubMed ID: 11453890
    [Abstract] [Full Text] [Related]

  • 10. Cytochrome P450 enzymes in drug metabolism: regulation of gene expression, enzyme activities, and impact of genetic variation.
    Zanger UM, Schwab M.
    Pharmacol Ther; 2013 Apr 15; 138(1):103-41. PubMed ID: 23333322
    [Abstract] [Full Text] [Related]

  • 11. Studies of flurbiprofen 4'-hydroxylation. Additional evidence suggesting the sole involvement of cytochrome P450 2C9.
    Tracy TS, Marra C, Wrighton SA, Gonzalez FJ, Korzekwa KR.
    Biochem Pharmacol; 1996 Oct 25; 52(8):1305-9. PubMed ID: 8937439
    [Abstract] [Full Text] [Related]

  • 12. Nortriptyline E-10-hydroxylation in vitro is mediated by human CYP2D6 (high affinity) and CYP3A4 (low affinity): implications for interactions with enzyme-inducing drugs.
    Venkatakrishnan K, von Moltke LL, Greenblatt DJ.
    J Clin Pharmacol; 1999 Jun 25; 39(6):567-77. PubMed ID: 10354960
    [Abstract] [Full Text] [Related]

  • 13. Quantitative structure-activity relationships (QSARs) for inhibitors and substrates of CYP2B enzymes: importance of compound lipophilicity in explanation of potency differences.
    Lewis DF, Ito Y, Lake BG.
    J Enzyme Inhib Med Chem; 2010 Oct 25; 25(5):679-84. PubMed ID: 20100069
    [Abstract] [Full Text] [Related]

  • 14. Role of human cytochrome P450 3A4 in the metabolism of DA-8159, a new erectogenic.
    Ji HY, Lee HW, Kim HH, Kim DS, Yoo M, Kim WB, Lee HS.
    Xenobiotica; 2004 Oct 25; 34(11-12):973-82. PubMed ID: 15801542
    [Abstract] [Full Text] [Related]

  • 15. Human cytochrome P450s involved in the metabolism of 9-cis- and 13-cis-retinoic acids.
    Marill J, Capron CC, Idres N, Chabot GG.
    Biochem Pharmacol; 2002 Mar 01; 63(5):933-43. PubMed ID: 11911845
    [Abstract] [Full Text] [Related]

  • 16. Theoretical investigation of differences in nitroreduction of aristolochic acid I by cytochromes P450 1A1, 1A2 and 1B1.
    Jerabek P, Martinek V, Stiborova M.
    Neuro Endocrinol Lett; 2012 Mar 01; 33 Suppl 3():25-32. PubMed ID: 23353840
    [Abstract] [Full Text] [Related]

  • 17. Computational Prediction of Inhibitors and Inducers of the Major Isoforms of Cytochrome P450.
    Rudik A, Dmitriev A, Lagunin A, Filimonov D, Poroikov V.
    Molecules; 2022 Sep 10; 27(18):. PubMed ID: 36144612
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.